Total Payments
$22,848
2024 Payments
$8,420
Companies
70
Transactions
922
Medicare Patients
339
Medicare Billing
$83,955
Payment Breakdown by Category
Food & Beverage$20,970 (91.8%)
Other$1,169 (5.1%)
Education$708.05 (3.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $20,970 | 898 | 91.8% |
| Long term medical supply or device loan | $1,147 | 12 | 5.0% |
| Education | $708.05 | 11 | 3.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21.71 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| MERZ NORTH AMERICA, INC. | $2,607 | 28 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,359 | 73 | $0 (2024) |
| Incyte Corporation | $1,457 | 61 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,355 | 61 | $0 (2024) |
| Janssen Biotech, Inc. | $956.85 | 43 | $0 (2024) |
| Gilead Sciences, Inc. | $771.43 | 26 | $0 (2024) |
| Eisai Inc. | $768.27 | 34 | $0 (2024) |
| Merck Sharp & Dohme LLC | $668.47 | 27 | $0 (2024) |
| Lilly USA, LLC | $623.87 | 28 | $0 (2024) |
| Seagen Inc. | $600.97 | 25 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,420 | 314 | Novartis Pharmaceuticals Corporation ($1,648) |
| 2023 | $7,686 | 293 | Merz North America, Inc. ($2,215) |
| 2022 | $4,937 | 237 | Incyte Corporation ($518.00) |
| 2021 | $1,483 | 73 | Pharmacyclics LLC, An AbbVie Company ($167.00) |
| 2019 | $183.14 | 3 | Seattle Genetics, Inc. ($129.06) |
| 2018 | $138.03 | 2 | Pharmacyclics LLC, An AbbVie Company ($120.00) |
All Payment Transactions
922 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.93 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $16.91 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/17/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $33.38 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/17/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $26.14 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.19 | General |
| 12/16/2024 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $26.25 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $33.66 | General |
| Category: Oncology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $15.33 | General |
| Category: Oncology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $0.13 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: Oncology | ||||||
| 12/08/2024 | MERZ NORTH AMERICA, INC. | Xeomin (Biological) | Food and Beverage | In-kind items and services | $88.93 | General |
| Category: Dermatology | ||||||
| 12/06/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $30.55 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Education | In-kind items and services | $25.95 | General |
| Category: Oncology | ||||||
| 12/05/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $0.99 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $26.48 | General |
| Category: Rare Disease | ||||||
| 12/01/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $29.31 | General |
| Category: Hematology/Oncology | ||||||
| 11/27/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $12.66 | General |
| Category: Oncology | ||||||
| 11/26/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo | Food and Beverage | In-kind items and services | $30.99 | General |
| Category: BioOncology | ||||||
| 11/22/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $30.16 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 184 | 429 | $117,485 | $50,133 |
| 2022 | 7 | 155 | 266 | $75,535 | $33,822 |
Total Patients
339
Total Services
695
Medicare Billing
$83,955
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 12 | 109 | $31,610 | $12,905 | 40.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 31 | 87 | $26,100 | $12,368 | 47.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 41 | 96 | $21,600 | $9,570 | 44.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 59 | 96 | $24,000 | $9,513 | 39.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 24 | 24 | $7,800 | $2,983 | 38.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $6,375 | $2,794 | 43.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 39 | 87 | $19,575 | $7,500 | 38.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 44 | $13,200 | $6,740 | 51.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 34 | 54 | $13,500 | $5,936 | 44.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 11 | 29 | $11,600 | $5,290 | 45.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 22 | 22 | $7,260 | $3,676 | 50.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 17 | 17 | $5,525 | $2,375 | 43.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 13 | 13 | $4,875 | $2,305 | 47.3% |
About Kevin Do
Kevin Do is a Hematology & Oncology healthcare provider based in Fountain Valley, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2015. The National Provider Identifier (NPI) number assigned to this provider is 1811384001.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Kevin Do has received a total of $22,848 in payments from pharmaceutical and medical device companies, with $8,420 received in 2024. These payments were reported across 922 transactions from 70 companies. The most common payment nature is "Food and Beverage" ($20,970).
As a Medicare-enrolled provider, Do has provided services to 339 Medicare beneficiaries, totaling 695 services with total Medicare billing of $83,955. Data is available for 2 years (2022–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Fountain Valley, CA
- Active Since 04/25/2015
- Last Updated 12/24/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1811384001
Products in Payments
- KISQALI (Drug) $1,504
- Xeomin (Biological) $989.19
- Lenvima (Drug) $768.27
- IMBRUVICA (Drug) $730.96
- JAKAFI (Drug) $721.79
- KEYTRUDA (Biological) $668.47
- CALQUENCE (Drug) $578.91
- ULTOMIRIS (Biological) $533.46
- MONJUVI (Drug) $512.41
- XPOVIO (Drug) $444.17
- VERZENIO (Drug) $394.12
- OPDIVO (Biological) $385.22
- CABOMETYX (Drug) $378.75
- Enhertu (Drug) $372.40
- ENHERTU (Biological) $310.84
- GILOTRIF (Drug) $295.93
- DARZALEX (Biological) $289.34
- REBLOZYL (Biological) $279.26
- Nubeqa (Drug) $264.02
- IBRANCE (Drug) $244.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Fountain Valley
Dr. Robert Moss, M.d, M.D
Hematology & Oncology — Payments: $103,336
Hematology & Oncology $103,336
Dr. Lalita Pandit, M.d, M.D
Hematology & Oncology — Payments: $72,643
Hematology & Oncology $72,643
Amol Rao, M.d, M.D
Hematology & Oncology — Payments: $57,618
Hematology & Oncology $57,618
Peyman Salimi-Tari, M.d, M.D
Hematology & Oncology — Payments: $51,086
Hematology & Oncology $51,086
Steven Yu, Md, MD
Hematology & Oncology — Payments: $31,830
Hematology & Oncology $31,830
Dr. Collin Vu, M.d, M.D
Hematology & Oncology — Payments: $18,185
Hematology & Oncology $18,185